EMA recommendation triggers $40M payment for blood disorder drug

Incyte and Novartis' blood disorder drug ruxolitinib was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use an enlarged spleen therapy in myelofibrosis patients. The recommendation will bring Incyte a $40 million milestone payment from Novartis. The drug is called Jakavi in Europe and Jakafi in the U.S., where it was approved by the FDA in November.

View Full Article in:

Bloomberg Businessweek · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN